Monitor NUVB stock for continued weakness due to convertible overhang. Note that the capped call may reduce dilution but does not eliminate it. Traders should watch for any early conversion triggers and potential short-selling by arbitrageurs.
Price Chart
Executive Summary
Nuvation Bio is issuing $250M of 0.75% convertible senior notes due 2032, with net proceeds of ~$241.2M. The offering is dilutive to common equity (initial conversion price of $7.84 per share vs. current $5.81) and increases total debt from $55.8M to $255.8M pro forma. Proceeds will repay a $50M secured loan and fund a $14.9M capped call transaction, with the balance for general corporate purposes. The convertible note overhang and increased leverage are near-term negatives for the stock.
Key Facts
- $250M principal of 0.75% Convertible Senior Notes due 2032
- Initial conversion price ~$7.84 per share, ~35% above last sale price of $5.81
- Net proceeds ~$241.2M (or ~$277.6M if overallotment exercised)
- Use: $14.9M for capped call, repay $50M Loan Agreement in full, remainder for general corporate purposes
- Pro forma total consolidated debt: $255.8M from $55.8M as of March 31, 2026
- Capped call limits dilution but initial conversion would add ~31.9M shares (9.2% of current float) if conversion triggered
Financial Impact
$250M additional debt; net dilution of up to ~31.9M shares if fully converted
Risk Factors
- Dilution from potential conversion of notes
- Increased leverage and interest expense
- Stock price pressure from convertible arbitrage hedging
- No immediate revenue generation to service additional debt
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-286494 |
| Document: d125210dexfilingfees.htm | 0001193125-26-286494 |
| Document: 0001193125-26-286494-index-headers.html | 0001193125-26-286494 |
| Document: 0001193125-26-286494-index.html | 0001193125-26-286494 |
| Document: 0001193125-26-286494.txt | 0001193125-26-286494 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Press Release | $4.70 | awaiting T+60 | — | $4.57 (−2.87%) |
Aug 6, 2026 11w ago | 8-K | $6.11 | awaiting T+60 | — | $4.57 (−25.29%) |
Jun 26, 2026 17w ago | 424B5 | $5.61 $6.10 | ▼ −8.73% | ▼ −4.35% | $4.57 (+18.63%) |
Jun 23, 2026 17w ago | 144 | $6.46 $6.07 | ▲ +6.04% | ▲ +8.88% | $4.57 (+29.33%) |
Jun 23, 2026 17w ago | 144 | $6.46 $6.07 | ▼ −6.04% | ▼ −8.88% | $4.57 (−29.33%) |
May 4, 2026 24w ago | 8-K | $4.83 $6.70 | ▲ +38.72% | ▲ +35.98% | $4.57 (−5.49%) |
Apr 21, 2026 26w ago | DEFA14A | $5.11 $5.64 | ▲ +10.37% | ▲ +3.47% | $4.57 (−10.67%) |
Apr 17, 2026 27w ago | 144 | $5.12 $5.90 | ▲ +15.23% | ▲ +8.46% | $4.57 (−10.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers